HomeCompareMTPR vs PFE

MTPR vs PFE: Dividend Comparison 2026

MTPR yields 1000000.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTPR wins by $188409716392645591040.00M in total portfolio value
10 years
MTPR
MTPR
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$188409716392645591040.00M
Annual income
$156,820,396,180,463,870,000,000,000.00
Full MTPR calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — MTPR vs PFE

📍 MTPR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTPRPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTPR + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTPR pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTPR
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$133,297,336,753,394,290,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, MTPR beats the other by $133,297,336,753,394,290,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTPR + PFE for your $10,000?

MTPR: 50%PFE: 50%
100% PFE50/50100% MTPR
Portfolio after 10yr
$94204858196322795520.00M
Annual income
$78,410,198,090,231,930,000,000,000.00/yr
Blended yield
83.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MTPR
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTPR buys
0
PFE buys
0
No recent congressional trades found for MTPR or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTPRPFE
Forward yield1000000.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$188409716392645591040.00M$51.1K
Annual income after 10y$156,820,396,180,463,870,000,000,000.00$27,210.54
Total dividends collected$186170298512243982336.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MTPR vs PFE ($10,000, DRIP)

YearMTPR PortfolioMTPR Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$50,010,700$50,000,000.00$9,161$701.38+$50.00MMTPR
2$116,900,941,356$116,847,429,906.54$8,610$859.79+$116900.93MMTPR
3$127,757,345,946,658$127,632,261,939,407.38$8,366$1,081.25+$127757345.94MMTPR
4$65,316,731,768,579,704$65,180,031,408,416,776.00$8,483$1,405.66+$65316731768.57MMTPR
5$15,641,708,257,005,480,000$15,571,819,354,013,100,000.00$9,084$1,907.24+$15641708257005.47MMTPR
6$1,759,286,910,766,321,500,000$1,742,550,282,931,325,600,000.00$10,418$2,732.78+$1759286910766321.50MMTPR
7$93,467,370,779,778,750,000,000$91,584,933,785,258,800,000,000.00$13,007$4,193.56+$93467370779778752.00MMTPR
8$2,373,712,470,630,401,000,000,000$2,273,702,383,896,037,800,000,000.00$18,010$7,005.87+$2373712470630401024.00MMTPR
9$29,522,729,170,263,285,000,000,000$26,982,856,826,688,750,000,000,000.00$28,216$12,979.89+$29522729170263285760.00MMTPR
10$188,409,716,392,645,600,000,000,000$156,820,396,180,463,870,000,000,000.00$51,081$27,210.54+$188409716392645591040.00MMTPR

MTPR vs PFE: Complete Analysis 2026

MTPRStock

MetaPower International, Inc. operates as a management-consulting and technology company in North America. The company offers Noble Production, a suite of automated processes and attendant services that provide heavy industrial facilities with the tools necessary to guide the evolution of their organization and its culture. It also offers a suite of services to support Noble Production. These services include assessment services that assist clients in determining their performance relative to OSHA's Voluntary Protection Program 1 Safety criteria; culture reform services, including training and consulting services; business process management services comprising Noble Production automated process customization and business process design services; and cause analysis services, including cause analysis training and event investigations for investigating and determining the cause of conditions and incidents. In addition, the company provides consulting services in various areas, including business process management, program design and implementation, process design, procedure development and implementation, business system planning and implementation, corrective action programs, cause analysis, process safety management, and culture change management. Further, it offers training courses in various aspects of position competency, including technical training, performance training, supervision and leadership training, and other skill and knowledge based training. The company was founded in 1996 and is based in Vancouver, Washington.

Full MTPR Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MTPR vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTPR vs SCHDMTPR vs JEPIMTPR vs OMTPR vs KOMTPR vs MAINMTPR vs JNJMTPR vs MRKMTPR vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.